Girding against Keytruda cliff, Merck splits oncology into standalone business unit
The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. | The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming medicines by splitting its core pharmaceutical business in two.
The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. | The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming medicines by splitting its core pharmaceutical business in two.
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
